Led · Equity · Apr 2026

Founded in 2010, Wingify runs VWO (Visual Website Optimizer), an experience optimization platform used by over 3,000 brands to run A/B tests, personalize visitor experiences and improve conversion rates. The company remained bootstrapped and profitable for more than 14 years before taking PE investment and recently underwent a significant ownership change when Everstone acquired roughly 80% in early 2025. Wingify reported FY25 revenue of Rs 401.56 crore, up 33.2% year-over-year, while net profit fell to Rs 23.83 crore from Rs 61.05 crore the prior year. It is merging with AB Tasty to create a larger global digital experience optimization platform; the combined entity will have over 800 employees across 11 offices with India accounting for just over half the headcount. Nearly 90% of the combined revenue is expected to come from the US and Europe, and company leadership has indicated plans to pursue additional inorganic growth opportunities.

Participated · Series A · Apr 2021

Innoveo provides an enterprise no-code platform, Innoveo Skye®, to accelerate digital transformation and speed up go-to-market strategies. The company serves industries including insurance, financial services and real estate. It has delivered more than 500 applications and processed over $1 billion in transactions for clients such as Zurich Insurance, Allianz, Chubb, Rakbank and Marriott. Led by CEO Amir Ghaffar, Innoveo intends to use new funding to grow its sales team and marketing activities and to expand strategic partnerships. The company also plans to further enhance its product offerings by accelerating platform development and R&D. Operations are based in Zurich, Switzerland.

Led · Series B · Jan 2020

Slayback Pharma focuses on complex generics and specialty pharmaceutical products, supported by an R&D team in India and operations in the U.S., India and Europe. Since its inception in 2011, the company has achieved multiple sole first-to-file ANDAs, 505(b)(2) filings, approvals and launches. Recent commercial successes include the Hydroxyprogesterone 5 ml vial generic ANDA—the first generic ANDA approved and launched in the U.S.—for which Slayback holds the largest market share, and prior launches such as Propofol Injectable Emulsion. The company employs a team of 85 people. Slayback plans to use new capital to expand and accelerate its differentiated pipeline of complex generic and specialty products. Its track record emphasizes execution on difficult products and a focus on regulated markets. Slayback Pharma is a New Jersey–based pharmaceutical research and development company focused on complex generic and specialty products. The company has filed numerous Abbreviated New Drug Applications (ANDAs) and 505(b)(2) applications with the FDA since early 2011 through out-licensing partners. Recent product efforts include Propofol Injectable Emulsion USP 1% and a Generic Zovirax (Acyclovir) Ointment 5%, announced last month. Slayback prioritizes bringing first generics to market and, over the past five years, developed two complex sterile products that became rare sole First-to-File ANDAs with Paragraph IV certification. The company says it is focused on expanding access to affordable health care. The new financing announced will be used to enhance and accelerate development of its portfolio.

Led · Equity · Jan 2017

OmniActive Health Technologies produces premium, scientifically-validated natural ingredients for dietary supplementation and nutritional fortification. The company supplies human nutrition brands and manufacturers worldwide and markets leading ingredient brands such as Lutemax®, Capsimax®, CurcuWIN®, Gingever, Xtenergy® and OmniXan®. It maintains R&D and manufacturing operations in Pune, Hosur and Thane in India, with sales and distribution across the U.S., Europe, India, Asia, Australia and Latin America. OmniActive is led by CEO Jim Hamilton and was founded in 2005 by Sanjaya Mariwala. The article reports a strategic growth investment from TA Associates and notes the founder has increased his personal holding, but provides no financial or operating metrics. No revenue or user metrics were disclosed in the article. OmniActive Health Technologies supplies naturally sourced ingredients for eye health, weight management and heart health to global nutraceutical companies that produce food supplements and nutritional fortification. Founded in 2005 and led by Managing Director Sanjaya Mariwala, the company has manufacturing facilities and R&D centres across India and Canada and sales and marketing presence in the US, Europe and Asia. Its core products target eye, weight and heart health markets. The company received a US$35m minority investment from The Everstone Group. OmniActive intends to use the funds to further accelerate growth in the nutraceuticals space and to diversify and expand its offerings via already identified acquisitions. In conjunction with the deal, Everstone’s Deep Mishra and nutraceutical expert Dr. Leendert Staal will join OmniActive’s board as nominee directors.

Led · Equity · Nov 2015

S Chand and Company is an education content provider and publisher whose offerings are primarily textbooks and related print materials. The company reported this year's revenue at $100 million, with 95% of revenue from print and 5% from digital services. S Chand aims to grow print at a CAGR of 18–20% in the coming years while increasing digital services to 25% of revenue within five years. It plans rapid expansion into non-infrastructure education by augmenting textbooks with multimedia and digital delivery, and is pursuing aggressive acquisitions of regional publishers. The company has previously bought Vikas Publishing House and Madhuban Educational Books for $20–25 million, will complete a buyout of Saraswati Publishing House this year, and recently invested $200,000 in edtech startup Smartivity Labs.